KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Accumulated Expenses (2016 - 2026)

Biocryst Pharmaceuticals filings provide 15 years of Accumulated Expenses readings, the most recent being $126.4 million for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 11.58% to $126.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $126.4 million, a 11.58% increase, with the full-year FY2025 number at $126.4 million, up 11.58% from a year prior.
  • Accumulated Expenses hit $126.4 million in Q4 2025 for Biocryst Pharmaceuticals, up from $118.8 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $126.4 million in Q4 2025 to a low of $23.5 million in Q1 2021.
  • Median Accumulated Expenses over the past 5 years was $79.5 million (2022), compared with a mean of $82.0 million.
  • Biggest five-year swings in Accumulated Expenses: soared 235.35% in 2021 and later fell 5.53% in 2023.
  • Biocryst Pharmaceuticals' Accumulated Expenses stood at $72.7 million in 2021, then rose by 20.5% to $87.6 million in 2022, then rose by 17.49% to $102.9 million in 2023, then grew by 10.12% to $113.3 million in 2024, then rose by 11.58% to $126.4 million in 2025.
  • The last three reported values for Accumulated Expenses were $126.4 million (Q4 2025), $118.8 million (Q3 2025), and $107.1 million (Q2 2025) per Business Quant data.